Cytotoxic Epstein-Barr virus T-cell epitopes derived from EBV structural antigens

摘要

Cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens, particularly gp85 and gp350 are provided. Preferred epitopes include: YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). EBV-specific CTL epitopes may be used in the treatment or prevention of nasopharyngeal carcinoma or Hodgkins disease, or for reducing the risk of infectious mononucleosis or post transplantation lymphoproliferative disease.